Literature DB >> 1742257

Autoradiographic and immunohistochemical study on the proliferative kinetics of intestinal metaplasia.

H S Bom1, C M Yoon, J S Rew, S K Choi, S W Juhng.   

Abstract

In order to elucidate the proliferative behavior of the intestinal metaplasia around gastric cancer, the authors used both in vitro tritiated thymidine (3H-thymidine) autoradiography and in vivo bromodeoxyuridine (BrdUrd) immunohistochemistry for labeling the proliferative cells of the normal pyloric glands and metaplastic gastric glands. The results of the methods were comparable: The labeling pattern and the rate of labeling were very similar. In the normal pyloric mucosa, the labeled cells were confined to the isthmus region, indicating that pyloric glandular cells are normally renewed from the isthmus region. On the other hand, a zone of the labeled cells was found in the lower half of the intestinalized mucosa, indicating that cell proliferation took place deep in the mucosa, just like the case of normal intestinal glands. The labeling indices of the pyloric mucosa were 19.4% by autoradiography and 18.0% by immunohistochemistry, and that of the intestinalized gastric glands were 25.2% by autoradiography and 24.2% by immunohistochemistry. In conclusion, both 3H-thymidine autoradiography and BrdUrd immunohistochemistry showed that the proliferative kinetics of the intestinalized gastric glands was similar to that of the normal intestinal glands rather than the pyloric glands, i.e. a lower level of proliferative zone and higher labeling index were present.

Entities:  

Mesh:

Year:  1991        PMID: 1742257      PMCID: PMC4535013          DOI: 10.3904/kjim.1991.6.1.8

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  23 in total

1.  Hazard of tritium as a deoxyribonucleic acid label in man.

Authors:  R OLIVER; L G LAJTHA
Journal:  Nature       Date:  1960-04-02       Impact factor: 49.962

2.  Intestinal metaplasia of the gastric mucosa. Endoscopic recognition and review of the literature.

Authors:  E R Korn
Journal:  Am J Gastroenterol       Date:  1974-04       Impact factor: 10.864

3.  Cell proliferation kinetics in the gastrointestinal tract of man. IV. Cell renewal in the intestinalized gastric mucosa.

Authors:  S J Winawer; M Lipkin
Journal:  J Natl Cancer Inst       Date:  1969-01       Impact factor: 13.506

4.  "Small intestinal type" and "colonic type" intestinal metaplasia of the human stomach, and their relationship to the histogenetic types of gastric adenocarcinoma.

Authors:  P S Teglbjaerg; H O Nielsen
Journal:  Acta Pathol Microbiol Scand A       Date:  1978-09

5.  Cell proliferation kinetics in the gastrointestinal tract of man. 3. Cell renewal in esophagus, stomach, and jejunum of a patient with treated pernicious anemia.

Authors:  B Bell; T P Almy; M Lipkin
Journal:  J Natl Cancer Inst       Date:  1967-05       Impact factor: 13.506

6.  Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors.

Authors:  A Russo; L Gianni; T J Kinsella; R W Klecker; J Jenkins; J Rowland; E Glatstein; J B Mitchell; J Collins; C Myers
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

7.  Sulphomucin colonic type intestinal metaplasia and carcinoma in the stomach. A histochemical study of 115 cases obtained by biopsy.

Authors:  C B Huang; J Xu; J F Huang; X Y Meng
Journal:  Cancer       Date:  1986-04-01       Impact factor: 6.860

8.  Role of intestinal metaplasia in the histogenesis of gastric carcinoma.

Authors:  J R Jass
Journal:  J Clin Pathol       Date:  1980-09       Impact factor: 3.411

9.  Cell kinetic studies of in situ human brain tumors with bromodeoxyuridine.

Authors:  T Hoshino; T Nagashima; J Murovic; E M Levin; V A Levin; S M Rupp
Journal:  Cytometry       Date:  1985-11

10.  Tritiated thymidine autoradiographic study on histogenesis and spreading of intestinal metaplasia in human stomach.

Authors:  T Hattori; S Fujita
Journal:  Pathol Res Pract       Date:  1979-01       Impact factor: 3.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.